{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:14Z","timestamp":1786980554435,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A 73-year-old male patient presented with anemia and was diagnosed with unresectable advanced gastric cancer with distant lymph node metastases. The biopsy specimen showed a poorly differentiated adenocarcinoma. Immunohistochemistry was negative for human epidermal growth factor receptor 2, positive for claudin- 18, and revealed a preserved mismatch repair status. A regimen of capecitabine, oxaliplatin, and zolbetuximab was chosen as the primary chemotherapy regimen. On day 2, the patient started complaining of nausea and decreased appetite, and his symptoms gradually worsened. Esophagogastroduodenoscopy performed on day 11 revealed an erythematous and edematous mucosa with white secretions throughout the stomach. A histopathological examination revealed epithalaxia at the surface and severe inflammatory cell infiltration in the lamina propria. These endoscopic and histological findings indicated zolbetuximab-related gastritis. His symptoms improved three weeks after the discontinuation of chemotherapy. Endoscopic and pathological improvements of the gastritis were confirmed three months after the discontinuation of zolbetuximab. This report describes the first case of prolonged severe gastrointestinal symptoms with severe gastritis caused by zolbetuximab, as demonstrated by endoscopic and histopathological evidence.<\/jats:p>","DOI":"10.1007\/s10120-025-01607-9","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:20:32Z","timestamp":1743772832000},"page":"705-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Zolbetuximab-related gastritis: a case report of the patient with prolonged gastrointestinal symptoms"],"prefix":"10.1007","volume":"28","author":[{"given":"Yuya","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9029-5081","authenticated-orcid":false,"given":"Hiroki","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shion","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Iribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"1607_CR1","doi-asserted-by":"crossref","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2023;401:1655\u201368","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"1607_CR2","doi-asserted-by":"crossref","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341","DOI":"10.1038\/s41591-023-02465-7"},{"key":"1607_CR3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, et al. Association of CLDN18 Protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. JPM. 2021;11:1095.","journal-title":"JPM"},{"key":"1607_CR4","doi-asserted-by":"crossref","unstructured":"Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, et al. claudin-18 , a Novel Downstream Target Gene for the T\/EBP\/NKX2.1 Homeodomain Transcription Factor, Encodes Lung- and Stomach-Specific Isoforms through Alternative Splicing. Molecular and Cellular Biology. 2001;21:7380\u201390","DOI":"10.1128\/MCB.21.21.7380-7390.2001"},{"key":"1607_CR5","doi-asserted-by":"crossref","unstructured":"Shimozaki K, Ooki K, Yamahata Y, Aoyama T, Yoshino K, Tamba M, et al. Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice. ESMO Gastrointest Oncol. 2025;7: published online","DOI":"10.1016\/j.esmogo.2024.100128"},{"key":"1607_CR6","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30:1487\u201395.","journal-title":"Ann Oncol"},{"key":"1607_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jphs.2024.08.005","volume":"156","author":"F Kinugasa","year":"2024","unstructured":"Kinugasa F, Kajikawa S, Weng J, Ugawa T, Fushiki H, Yamanaka Y, et al. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. J Pharmacol Sci. 2024;156:161\u201370.","journal-title":"J Pharmacol Sci"},{"key":"1607_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/j.gastro.2011.10.040","volume":"142","author":"D Hayashi","year":"2012","unstructured":"Hayashi D, Tamura A, Tanaka H, Yamazaki Y, Watanabe S, Suzuki K, et al. Deficiency of claudin-18 causes paracellular H+ leakage, up-regulation of interleukin-1\u03b2, and atrophic gastritis in mice. Gastroenterology. 2012;142:292\u2013304.","journal-title":"Gastroenterology"},{"key":"1607_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.32074\/1591-951X-163","volume":"112","author":"G Pennelli","year":"2020","unstructured":"Pennelli G, Grillo F, Galuppini F, Ingravallo G, Pilozzi E, Rugge M, et al. Gastritis: update on etiological features and histological practical approach. Pathologica. 2020;112:153\u201365.","journal-title":"Pathologica"},{"key":"1607_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.acr.2022.02.007","volume":"155","author":"HI Akbarali","year":"2022","unstructured":"Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022;155:131\u201366.","journal-title":"Adv Cancer Res"},{"key":"1607_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115787","volume":"216","author":"Y He","year":"2023","unstructured":"He Y, Zheng J, Ye B, Dai Y, Nie K. Chemotherapy-induced gastrointestinal toxicity: pathogenesis and current management. Biochem Pharmacol. 2023;216: 115787.","journal-title":"Biochem Pharmacol"},{"key":"1607_CR12","doi-asserted-by":"publisher","first-page":"2408852","DOI":"10.1080\/21645515.2024.2408852","volume":"20","author":"F Su","year":"2024","unstructured":"Su F, Fan WX, Zhang Y, Zhang XL, Du YY, Li WL, et al. A systematic review of gastritis as an immune-related adverse event in clinical interventions. Hum Vaccin Immunother. 2024;20:2408852.","journal-title":"Hum Vaccin Immunother"},{"key":"1607_CR13","doi-asserted-by":"publisher","first-page":"E982","DOI":"10.1055\/a-1839-4303","volume":"10","author":"Y Sugiyama","year":"2022","unstructured":"Sugiyama Y, Tanabe H, Matsuya T, Kobayashi Y, Murakami Y, Sasaki T, et al. Severe immune checkpoint inhibitor-associated gastritis: a case series and literature review. Endosc Int Open. 2022;10:E982\u20139.","journal-title":"Endosc Int Open"},{"key":"1607_CR14","first-page":"472","volume":"38","author":"A Waheed","year":"2024","unstructured":"Waheed A, Saleem MN, Shah Y, Gul MH, Hussaini H, Wardak AB. Efficacy and safety of zolbetuximab in gastric cancer. Oncology (Williston Park). 2024;38:472\u20134.","journal-title":"Oncology (Williston Park)"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01607-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01607-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01607-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T09:58:01Z","timestamp":1750154281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01607-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01607-9","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for publication of case details and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}